Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
Kui K. Chan, Timothy J.C. Tan, Krishna K. Narayanan, et al.
Science Advances (2021) Vol. 7, Iss. 8
Open Access | Times Cited: 136

Showing 26-50 of 136 citing articles:

AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance
Nishank Raisinghani, Mohammed Alshahrani, Grace Gupta, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1458-1458
Open Access | Times Cited: 10
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 8
Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021
Thomas Wilton, Erika Bujáki, Dimitra Klapsa, et al.
mSystems (2021) Vol. 6, Iss. 3
Open Access | Times Cited: 52
RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
Gustavo Lopardo, Waldo Belloso, Esteban C. Nannini, et al.
EClinicalMedicine (2021) Vol. 34, pp. 100843-100843
Open Access | Times Cited: 49
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses
Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 48
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Pei‐Yong Shi, Xuping Xie, Jing Zou, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 45
Rapid characterization of spike variants via mammalian cell surface display
Kamyab Javanmardi, Chia‐Wei Chou, Cynthia I. Terrace, et al.
Molecular Cell (2021) Vol. 81, Iss. 24, pp. 5099-5111.e8
Open Access | Times Cited: 45
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
Joshua J. Sims, Jenny A. Greig, Kristofer T. Michalson, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 7, pp. e1009544-e1009544
Open Access | Times Cited: 42
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
Matthew D. Hall, James M. Anderson, Annaliesa S. Anderson, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. Supplement_1, pp. S1-S21
Open Access | Times Cited: 41
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection
Luise Hassler, Jan Wysocki, Ian Gelarden, et al.
Journal of the American Society of Nephrology (2022) Vol. 33, Iss. 7, pp. 1293-1307
Open Access | Times Cited: 36
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
Yaozong Chen, Lulu Sun, Irfan Ullah, et al.
Science Advances (2022) Vol. 8, Iss. 28
Open Access | Times Cited: 36
Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy
Harry Ridgway, Christos T. Chasapis, Konstantinos Kelaidonis, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 1029-1029
Open Access | Times Cited: 33
Engineering ACE2 decoy receptors to combat viral escapability
Takao Arimori, Nariko Ikemura, Toru Okamoto, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 838-851
Open Access | Times Cited: 30
The first three waves of the Covid-19 pandemic hint at a limited genetic repertoire for SARS-CoV-2
Trudy M. Wassenaar, Visanu Wanchai, Gregory S. Buzard, et al.
FEMS Microbiology Reviews (2022) Vol. 46, Iss. 3
Open Access | Times Cited: 28
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
Xuemei He, Cai He, Weiqi Hong, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 932-971
Open Access | Times Cited: 17
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
Saya Moriyama, Yuki Anraku, Shunta Taminishi, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 16
Engineered Receptor Capture Combined with Mass Spectrometry Enables High-Throughput Detection and Quantitation of SARS-CoV-2 Spike Protein
Neil Bate, Dan Lane, Siân E. Evans, et al.
JACS Au (2025) Vol. 5, Iss. 2, pp. 747-755
Open Access
Polarity‐Dominated Stable N97 Respirators for Airborne Virus Capture Based on Nanofibrous Membranes
Qifei Wang, Yingzhen Wei, Wenbo Li, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 44, pp. 23756-23762
Open Access | Times Cited: 36
Fast Prediction of Binding Affinities of the SARS-CoV-2 Spike Protein Mutant N501Y (UK Variant) with ACE2 and Miniprotein Drug Candidates
Alexander H. Williams, Chang‐Guo Zhan
The Journal of Physical Chemistry B (2021) Vol. 125, Iss. 17, pp. 4330-4336
Open Access | Times Cited: 33
Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2
Kien Nguyen, Srirupa Chakraborty, Rachael A. Mansbach, et al.
Viruses (2021) Vol. 13, Iss. 5, pp. 927-927
Open Access | Times Cited: 33
Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, et al.
Science Advances (2022) Vol. 8, Iss. 47
Open Access | Times Cited: 26
An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages
Sandro Satta, Zhaojie Meng, Rebecca Hernandez, et al.
Theranostics (2022) Vol. 12, Iss. 6, pp. 2639-2657
Open Access | Times Cited: 23
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
Lianghui Zhang, Krishna K. Narayanan, Laura Cooper, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
CESSAT: A chemical additive-enhanced single-step accurate CRISPR/Cas13 testing system for field-deployable ultrasensitive detection and genotyping of SARS-CoV-2 variants of concern
Yunxiang Wang, Hong Chen, Huixia Gao, et al.
Biosensors and Bioelectronics (2023) Vol. 229, pp. 115238-115238
Open Access | Times Cited: 14

Scroll to top